MiRus Submits IPO Filing Following FDA Approval of MoRe® Molybdenum-Rhenium Alloy Implant for Adult Spinal Deformity

VCBeat (WeChat ID: vcbeat) has learned that MiRus, a medical device company, recently received approval from the U.S. Food and Drug Administration (FDA) for its novel molybdenum-rhenium alloy medical implant, named MoRe. This marks the first FDA-approved medical implant made from a proprietary molybdenum-rhenium alloy, indicated for adult spinal deformity surgery.

It is reported that spinal deformity is a common spinal disorder caused by deviations of the spine from its normal position in the coronal, sagittal, or axial planes. It primarily manifests as kyphosis, postural asymmetry, uneven shoulder height, and short stature. This condition can impair normal growth and development in patients; in severe cases, it may lead to declined cardiopulmonary function, limited limb mobility, and even paralysis.

In 2018, NASS (North American Spine Society), the world’s largest professional academic organization for spine surgery, presented MiRus with the Spine Technology Award in recognition of MoRe’s outstanding achievements in the field of spine surgery.

MoRe is a medical implant made from a proprietary molybdenum-rhenium alloy. Compared with traditional implant materials, molybdenum-rhenium alloy offers unparalleled advantages, making it an ideal alternative to conventional materials for medical implants. MoRe implants are smaller and lighter than traditional ones, reducing adverse effects on surrounding bone tissue and enabling better integration with the natural contour of the bone. Their excellent ductility and strength allow physicians to customize the shape of the implant to match the patient’s specific bone anatomy. Furthermore, MoRe enhances safety by reducing the risk of implant fracture. Unlike implants containing nickel, cobalt, or chromium, which frequently cause biocompatibility issues or allergic reactions, MoRe does not pose such concerns.

It is understood that molybdenum-rhenium (Mo-Re) alloys are typically used in high-temperature conditions within industrial and chemical fields, such as heating elements for high-temperature furnaces, high-temperature thermocouples, long-life grids for microwave communications, and core heating tubes for space reactors. In recent years, researchers have discovered that Mo-50Re alloy (a molybdenum-rhenium alloy containing 52.5% molybdenum and 47.5% rhenium) exhibits favorable biological properties and can be used as an implant material in surgical procedures. Major medical companies have begun to focus on Mo-Re alloys in their research and development of medical implant technologies, with MiRus’s MoRe product currently at the forefront of this technology.

Jay S. Yadav, MD, Founder and CEO of MiRus, stated, “MoRe is the culmination of decades of research by our company’s scientists and engineers in collaboration with world-class metallurgists, representing the most significant advancement in medical implant material technology in forty years. I believe MoRe will profoundly disrupt the medical device industry.”

Currently, MoRe is only applicable in spinal deformity surgery. MiRus aims to extend the use of MoRe to other orthopedic procedures, such as those involving the foot and ankle. Additionally, the FDA has required MiRus to conduct rigorous scientific investigations on MoRe to further establish the safety and efficacy of molybdenum-rhenium alloy as a material for spinal implants. In compliance with FDA requirements, Jordan Bauman, Vice President of Regulatory Affairs at MiRus, is leading researchers in large-scale studies to obtain comprehensive and detailed data.

About Mirus

Mirus, headquartered in Georgia, USA, was founded in 2016 as a medical device company focused on developing novel therapeutic solutions for spinal deformities and degenerative bone diseases. Mirus was formerly known as ICON Interventional.

(Compiled by Jiao Yanli)